Quinnova Pharmaceuticals, Inc. Launches Salvax Duo

NEWTOWN, Pa.--(Business Wire)--
Quinnova Pharmaceuticals, Inc. announced today the launch of Salvax Duo, which
contains one unit of Salvax Foam (containing 6% salicylic acid) and one unit of
Hydro 40 Foam (containing 40% urea). Salvax Duo is available by prescription
only and both Salvax Foam and Hydro 40 Foam are indicated for hyperkeratotic
conditions such as dermatitis, psoriasis, xerosis, ichthyosis, eczema,
keratosis, keratoderma and dry, rough skin, as well as corns and calluses.
Additionally, both products use Quinnova`s patented Proderm Technology, a
water-lipid based formulation that has anti-inflammatory, skin repair and
protective properties.

"In our continued effort to provide physicians and patients with added value in
the treatment and maintenance of a variety of hyperkeratotic conditions, we are
pleased to introduce Salvax Duo to the market," said Jeffrey S. Day, Quinnova`s
President and CEO. "Containing Salvax Foam and Hydro 40 Foam, with both of these
products sharing the therapeutic, cosmetic and ease-of-use advantages of Proderm
Technology, we hope Salvax Duo becomes a 'go to' product for the treatment of
chronic cases of hyperkeratotic conditions."

The water-lipid nature of the Proderm Technology allows for the ingredients to
be rapidly absorbed and incorporated into the outer layers of the skin.
Furthermore, the Proderm Technology is non-comedogenic and provides a
cosmetically elegant feel in addition to ease of application because it is
non-greasy and spreads easily. Unlike some topical foam preparations, Proderm
Technology does not use either alcohol or other organic solvents, therefore it
is well tolerated by patients.

Quinnova Pharmaceuticals` sales force calls on dermatologists and podiatrists
across the United States.

About Quinnova Pharmaceuticals, Inc.

Quinnova Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of prescription drug products based on
innovative topical drug delivery platforms. For more information, please visit
www.quinnova.com.

Quinnova Pharmaceuticals, Inc.
Jurgen van den Woldenberg, 215-550-2008
jwoldenberg@quinnova.com

Copyright Business Wire 2009